Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, mice with clinical GVHD exhibited increases in the splenic human CD4<sup>+</sup>:CD8<sup>+</sup> T cell ratio, serum human interferon (IFN)-γ and intestinal human IL-17 expression compared to mice with subclinical GVHD.
|
30743002 |
2019 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-17A Contributes to Lung Fibrosis in a Model of Chronic Pulmonary Graft-versus-host Disease.
|
31658231 |
2019 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, IL-17 reduced the infiltration of macrophages into the GVHD tissues.
|
27748733 |
2018 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
hpMSCs reduced weight loss, along with IL-6 and IL-17 production to prolong the survival of GVHD mice.
|
30393022 |
2018 |
Graft-vs-Host Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the clinic, high levels of both IL-17A and IL-22 expression are present in the skin of patients with GVHD after allo-SCT.
|
28941323 |
2018 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Allogeneic BMT recipients deficient in IL-17A also develop accelerated GVHD, suggesting MAIT cells likely regulate GVHD, at least in part, by the generation of this cytokine.
|
29629900 |
2018 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Donor T-cell-derived interleukin-17A (IL-17A) can mediate late immunopathology in graft-versus-host disease (GVHD), however protective roles remain unclear.
|
28137828 |
2017 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients who developed GVHD were characterized by a predominant pro-inflammatory response (IL-17A (10.02 vs 0.43pg/mL, p=0.006), TNF-α (54.57 vs 0.81pg/mL, p=0.001)), in contrast to a deficient suppressor profile (IL-10 (7.87 vs 41.37pg/mL, p=0.003)) and Tregs (0.95% vs 1.52%, p=0.004).
|
29101827 |
2017 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that pathogenic human Th17 cells induce cutaneous GVHD via IL-17-dependent pathways.
|
27862942 |
2017 |
Graft-vs-Host Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of IL-17 gene polymorphisms and serum level with graft versus host disease after allogeneic hematopoietic stem cell transplantation.
|
24968286 |
2014 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, upon ex vivo reisolation of transferred wild-type Treg, we detected little or no Treg-mediated IL-17 production upon GVHD induction.
|
23921175 |
2013 |
Graft-vs-Host Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17.
|
22077062 |
2012 |